Patients with treatment resistant depression use more resources and have significantly higher health care costs, according to a retrospective cohort published in JMCP.
A cost impact analysis of Medicare patients with Alzheimer's disease and dementia in their final years of life found that families and Medicaid bear the bear most of the cost burden. The authors of this JMCP article propose the need to better integrate Medicare and Medicaid to fund and improve patient outcomes.
Press Release: The Trump Administration today pulled its proposed rule to eliminate safe harbor protections for rebates paid by pharmaceutical manufacturers to PBMs and health plans in Medicare and Medicaid programs.
Where We Stand: AMCP supports the use of value frameworks as a resource for determining the value of pharmaceuticals and other health technologies when the Frameworks are based on sound methods using good scientific evidence and economic models.
Press Release: Focusing on what’s best for the patient, leveraging technology to perform real-time benefit checks, and developing trust and transparency among stakeholders are some of the suggestions to emerge from AMCP’s recent Partnership Forum on “Optimizing Prior Authorization for Appropriate Medication Selection.”
A retrospective cohort study published in JMCP found that MTM programs targeting a resolution of medication-related problems resulted in reductions in health care utilization and increased medication adherence.